Back to mobile site

More on ERNA

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (10.0 Score)

Upcoming Events

- Earnings (8/17/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Eterna Therapeutics (NQ:ERNA)
Delayed: 4.45 -0.09 (1.98%)
Prev. Close $4.54  
Open$4.37 
52 Wk High$ 
52 Wk Low$ 
Day High$4.68 
Day Low$4.28 
P/E N/A  
EPS$ 
Volume57,738 

Friends, Peers and Foes (?): LLY, NTHI VIVS (more...)

Jul 15, 2026 10:43 AM Three Biotechs Deliver Catalysts to Watch
Jul 15, 2026 07:50 AM Ernexa's ERNA-101 combo shows tumor clearance in animal study
Jul 15, 2026 07:50 AM Ernexa Therapeutics Receives Independent Validation of ERNA-101 with Complete Tumor Clearance and Durable Survival in Ovarian Cancer Models Ahead of Planned Clinical Entry
Jul 14, 2026 09:01 AM Ernexa targets Q4 2026 for first-in-human ovarian cancer trial
Jul 14, 2026 09:01 AM Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026
Jul 2, 2026 04:41 PM Form 8-K Ernexa Therapeutics Inc. For: Jul 02
Jul 2, 2026 04:31 PM Form 8-K Ernexa Therapeutics Inc. For: Jul 01
Jun 26, 2026 04:31 PM Form 8-K Ernexa Therapeutics Inc. For: Jun 22
Jun 25, 2026 09:15 AM Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients
Jun 17, 2026 08:48 AM Ernexa Therapeutics plans IND filing for cancer cell therapy in Q3 2026
View All Articles

Entities mentioned with ERNA

View All Entities